Genome Balance Sheet Health
Financial Health criteria checks 5/6
Genome has a total shareholder equity of ₩109.7B and total debt of ₩22.0B, which brings its debt-to-equity ratio to 20.1%. Its total assets and total liabilities are ₩158.0B and ₩48.3B respectively.
Key information
20.1%
Debt to equity ratio
₩22.05b
Debt
| Interest coverage ratio | n/a |
| Cash | ₩80.19b |
| Equity | ₩109.66b |
| Total liabilities | ₩48.30b |
| Total assets | ₩157.96b |
Recent financial health updates
Is Genome (KOSDAQ:314130) A Risky Investment?
Jul 03
Is Genome (KOSDAQ:314130) Using Debt In A Risky Way?
Mar 08Genome (KOSDAQ:314130) Is In A Good Position To Deliver On Growth Plans
Mar 17Recent updates
Is Genome (KOSDAQ:314130) A Risky Investment?
Jul 03Investors Still Aren't Entirely Convinced By Genome & Company's (KOSDAQ:314130) Revenues Despite 49% Price Jump
May 27Positive Sentiment Still Eludes Genome & Company (KOSDAQ:314130) Following 25% Share Price Slump
Apr 11Is Genome (KOSDAQ:314130) Using Debt In A Risky Way?
Mar 08Genome (KOSDAQ:314130) Is In A Good Position To Deliver On Growth Plans
Mar 17Financial Position Analysis
Short Term Liabilities: A314130's short term assets (₩91.8B) exceed its short term liabilities (₩28.1B).
Long Term Liabilities: A314130's short term assets (₩91.8B) exceed its long term liabilities (₩20.2B).
Debt to Equity History and Analysis
Debt Level: A314130 has more cash than its total debt.
Reducing Debt: Insufficient data to determine if A314130's debt to equity ratio has reduced over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: A314130 has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: A314130 has sufficient cash runway for 1.7 years if free cash flow continues to reduce at historical rates of 30% each year.